

*République Algérienne Démocratique et
Populaire
Ministry of Higher Education and Scientific
Research
University A. MIRA-BEJAIA*

*Faculty of Natural and Life Sciences
Microbiology Department
Fundamental Microbiology Specialty*



Réf :

Dissertation

To obtain the diploma

Master's degree

Characterization of the resistance mechanisms of Acinetobacter baumannii isolated at the CHU of ORAN

**Presented by :
DJOUDI Zahra & LAIB Razika**

In front of a jury composed of :

Pr TOUATI .A	Professor	President
Ms ZAIDI Fatma Zohra	MCB	Promoter
Ms Mairi Assia	MCB	Examiner

Academic year:2022-2023

Acknowledgements

*First and for most, our sincere gratitude to our lord,
Allah, forgiving us the opportunity to start this
study and to have given us the strength to finish it.*

*Before we begin any development of our modest work,
we would like to thank everyone who has contributed to
its completion.*

*we would like to thanks Mr TOUAT.I A for his reception
in his laboratory.*

*We thank our supervisor ZaidiF.Z who knew how to
guide and orient us with patience and pedagogy and
who amazed us with her ideas, all as original as the
others, a true source of inspiration.*

*We would also like to thank all them members of the jury
for having taken their precious time to evaluate our
manuscript thoroughly PrTouati.Aand MAIRI.A*

Dedicace

*I dedicate this work to my very dear parents that they find here
All my gratitude for their support throughout my studies
There are no words to describe how much my parent has meant to
me all my life.*

*They have given me so much, thanks for your faith in me,
My lovely sisters Narimene , Maissa and Lydia
My little angels Amina and Meriem
for his support, his love, and his encouragement, thank you for helping
and supporting me*

*To my best friend Wissem , Yasmine and Hafida who has always
been there for me, my friends Lydia and Salwa.*

*To my binomial and friend Razika with whom I shared very good
moments and to whom I wish a lot of success as well as to all his
family*

*For those which gave me everything without anything in return
And finally all those who contributed to the realization of this work*

Zahra 

Dedicae

*With the help of Almighty God, I was able to produce this work,
which I dedicate to you:*

*To my very dear Father, I would like to pay tribute to you on this
memorable day for me, dear Dad, I would have liked you to be there
but I know that you are proud of me where you are, and your love I
will carry forever, I owe you my humble and profound thanks for
all your sacrifices,*

May God welcome you in to his vast paradise, Daddy dearest...

*To my dearest Mother, So many sentences and expressions cannot
express my gratitude and appreciation. You are my source of
willpower, dear Mum, I owe you my deepest thanks for the sense of
perseverance you taught me throughout my studies, your sacrifice,
your advice and your encouragement, may God keep you in very
good health for me.*

*To my dearest sisters, Souhila and Sarah, and my little niece
Maroua;*

*You are my source of life, I owe you so many thanks for all your
encouragement, your support and your unconditional love.*

*To my maternal and paternal family to
my dearest Grand father and his wife*

*To all my uncles, with the exception of my dear Madjid and
Azzedine*

*To my dear cousins, each in their own right, especially Meriem
and Rima and her children Walid and Wafa.*

*To my partner and best friend Zahra, thank you for your kindness,
your patience, your trust, your friendship and all the effort you
put into this work. To all my friends, and my dear friend Céline.*

Thank you to everyone

Summary

List of abbreviations

List of figures

List of tables

Introduction 1

Bibliography..... 2

Part1: Material and method

I. Bacterial strains.....	10
II. Isolation and identification of <i>A. Baumannii</i>	10
III. Antibiotic susceptibility studies(antibiograms).....	10

Part2: Results

➤ Phenotype test.....	12
➤ Distribution of <i>A. baumannii</i> isolates by type of sample.....	12
➤ Distribution of <i>A. baumannii</i> strains by department.....	13
➤ Rate of resistance of <i>A. baumannii</i> strains to the various antibiotics Tested	14
➤ Distribution of <i>A. baumannii</i> by sex.....	15

Part3: Discussion and conclusion

Discussion16

Conclusion20

Listofabbreviations

AmK: Amikacine.

CA-SFM : Comité de l'Antibiogramme de la Société Française de Microbiologie

CAZ : Cefazidime

CIP:Ciprofloxacin

CS : Colistine

CHDLs:Carbapenem-hydrolyzingclassDbeta-lactamases

CSF:Cerebrospinalfluid

Dox :Doxycycline

ESBL:Extended-spectrum β -lactamase

GeN: Gentamicine

gyrA:DNAgyrase gene

IMP: Imipeneme

IMA:MedicineInterneA

IPD:InfectionsandParasiticDiseases

Lvx: Levofloxacin

LPS:Lipopolysaccharide

Listofabbreviations

mat:Maternity

MDR:Multidrugresistanc

NDM:NewDelhimetallo- β -lactamase

NFC:Nouarfadelaclinic

OXA : Oxacilline / oxacillinase .

OMPA:Outer Membrane Proteins

OMA : Outer membrane

PIP:Piperacilline

parC:GenecodingfortheCsubunitoftopoisomeraseIV

PIP:Pipéracilline

Pp:Pneumologyandphthisology

Pavillon 5 : Gastroentrology

Pavillon 7 : Dermatology

PBPs:Penicillin-bindingproteins

QRDR:Quinoloneresistance-determiningregion

SIM:Seoul Imipenemase

SXT:Triméthoprimesulfametoxazole

Listofabbreviations

Sca:surgicalclinicsA

TCC:Ticarcilline+clavulanic acid

TIC:Ticarcilline

TOB: Tobramycine

List of Figures and Tables

List of figures

Figure1: image of negative citrate test.....	10
Figure2: Distribution of <i>A. baumannii</i> strains by type of sample	11
Figure3: Distribution of <i>A. baumannii</i> strains by department	12
Figure4: Rate of resistance of <i>A. baumannii</i> strains to the various antibiotics tested	13
Figure5: Distribution of <i>Acinetobacter baumannii</i> by sex.....	13

List of tables

Table1: The antibiotics tested are listed in Table N° 1: (CA-SFM 2018).	11
--	-----------

Introduction

Introduction

The origin of the term "antibiotic" can be traced back to the word "antibiose" first used by Paul Vuillemin in 1890 in his publication as an antonym to "symbiose" to describe the antagonistic action between different microorganisms. It was not until 1928 that penicillin was discovered, and subsequently, several classes of antibiotics were developed with mechanisms of action that include inhibition of cell wall synthesis, depolarization of the cell membrane, inhibition of protein synthesis, inhibition of nucleic acid synthesis, and inhibition of metabolic pathways in bacteria. The discovery of antibiotics revolutionized modern medicine until the 1950s, after which resistant strains started to emerge (**Kyriacos C Nicolaou and Stephan Rigol,2017 ; Wanda C Reygaert, 2018 ; Matt Hutchings 1 and al., 2019**).

Antimicrobial resistance mechanisms fall into four main categories: limit in uptake of a drug; modifying a drug target; inactivating a drug; active drug efflux. Intrinsic resistance may make use of limiting uptake, drug inactivation, and drug efflux; acquired resistance mechanisms used may be drug target modification, drug inactivation, and drug efflux., (**Mahon CR, Lehman DC, Manuselis G, 2014**).

The emergence and spread of this bacteria resistance caused by many factors include: increased consumption of antimicrobial drugs, both by humans and animals; and improper prescribing of antimicrobial therapy (**Wanda C Reygaert, 2018**).

The ESKAPE pathogen group has gained clinical importance due to their high and increasing resistance, as well as their ability to evade antibiotic treatment and exhibit novel concepts of transmission, pathogenesis, and resistance, as named by the Infectious Diseases Society of America (IDSA). This group includes *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species (**VishvanathTiwari , 2018**).

Nosocomial infections with *Acinetobacter baumannii* are responsible for an increase in mortality, longer hospital stays and higher hospital costs (**Naijaand al.,2009**), with clinical manifestations such as : ventilator-associated pneumonia, blood stream infections, urinary tract infections and meningitis (**Hing Jian Meaand al.,2021**).

In Algeria, numerous studies have focused on the resistance mechanisms of *A.baumannii*. Therefore, our objective was to investigate the prevalence of *A.baumannii* infections at the Oran University Hospital (CHU d' Oran) and determine the antibiotic resistance profiles of its strains.

Bibliography

Bibliography

Currently, the genus *Acinetobacter* comprises 74 species (**Jeong Ho Jeon and al., 2022**). The history of the *Acinetobacter* genus dates back to the beginning of the 20th century when a Dutch bacteriologist in 1911 described an organism called *Micrococcus calcoaceticus*, which was isolated for the first time on a minimal medium enriched with calcium acetate (**Dijkshoorn, 2008; Doughari and al., 2011**). During the following decades, similar microorganisms were described and attributed to at least 15 different genera and species. It was only in 1954 that Brisou and Prevot suggested the genus *Acinetobacter* (from the Greek "akinetos"; nonmotile), based on two characteristics: inability to move and non-pigmented (**Brisou and Prevot, 1954; Jung and Park, 2015**). In 1968, Baumann et al. placed all such isolates in one genus, *Acinetobacter*, which was accepted by the committee on the taxonomy of *Moraxella* and Allied Bacteria four years later. Using DNA/DNA hybridization techniques, *Bouvet and Grimont* succeeded in distinguishing 12 genomic species (**Peleg and al., 2008**). There has been a lot of confusion about the taxonomy of the genus *Acinetobacter*, which is finally taxonomically classified as follows: Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales; Moraxellaceae, Genus: *Acinetobacter* (**Jung J, Park W, 2015**).

Among *Acinetobacter* species, *Acinetobacter baumannii* is the most important member associated with hospital-acquired infections worldwide. It is a short bacilli or cocci, often in diploid or short chain formation, with a cell structure of Gram negative bacteria. For exam microscopic, it is a short, plump, typically 1.0 to 1.5 µm by 1.5 to 2.5 µm in size (**Jung and Park, 2015**), catalase positive, oxidase negative, citrate positive, urease positive, hemolyse negative, asporulated, many strains are unable to reduce nitrates to nitrites and the optimum temperature is 33–35°C, however, *A. baumannii* has the particularity of being able to grow between 41°C and 44°C (**Fariba and al., 2019; Doughari and al., 2011**), non motile and non fermenting coccobacilli, DNA G+C content of 39% to 47% (**Almasaudi, 2018**).

A. baumannii has emerged as the foremost nosocomial pathogen with significant implications for human health, owing to its escalating incidence and the emergence of multidrug-resistant (MDR) strains (**Nowak & Paluchowska, 2016**). Hospital-acquired infections caused by *A. baumannii* are most commonly encountered in intensive care units, particularly among critically ill patients (**Nowak & Paluchowska, 2016**). The primary

Bibliography

modes of transmission involve contact with contaminated hospital equipment or direct exposure to health care personnel who have previously countered the microorganism (Nowak & Paluchowska, 2016).

Acinetobacter baumannii is responsible for a diverse array of nosocomial infections, including hospital-acquired and community-acquired pneumonia, bacteremia, endocarditis, skin and soft tissue infections, surgical site infections, catheter-associated urinary tract infections, and meningitis, among others (Nowak & Paluchowska, 2016). In most cases, the acquisition of *A. baumannii* infections is attributed to exposure from persistently contaminated hospital equipment or contact with healthcare workers (Maragakis and al., 2004 ; Dijkshoorn and al., 2007).

A previous comprehensive systematic review and meta-analysis, encompassing numerous studies, identified several risk factors associated with *A.baumannii* infections, including inadequate antimicrobial therapy, prolonged stay in intensive care units, mechanical ventilation, advanced age, comorbidities such as renal failure, malignancies, cancer, AIDS, immunosuppression, and leukemia (Nimer, 2022).

Immunocompromised individuals, especially those with prolonged hospitalization, constitute a high-risk population for acquiring infections caused by this bacterium (Zhou and al., 2019). Furthermore, other factors such as therapeutic procedures, endoscopic interventions, prolonged hospital stays, recent surgical interventions, prior exposure to antimicrobial agents, use of central venous catheters, previous hospitalization, nursing home residence, and local colonization pressure on vulnerable patients have been identified as significant risk factors for the development of nosocomial *A. baumannii* infections (Zhou and al., 2019).

For a long time, the antibiotic therapy used against *A. baumannii* infections included beta-lactams (penicillins, cephalosporins, carbapenems, monobactams, and beta-lactamase inhibitors) (Ioannis Kyriakidis.,2021), aminoglycosides, quinolones and carbapenems.(Nukaga and al, 2003). The excessive use of broad-spectrum antibiotics such as third-generation cephalosporins, aminoglycosides exert a selection pressure that plays a very important role in the emergence of multi-resistant strains (ALLAL Hassiba HADBI

Bibliography

Manel, 2018) and additionally the presence of genes linked to antimicrobial drug resistance was detected in both the core and accessory genomes of the species. Within the accessory genome, antimicrobial resistance genes were identified with in foreign genomic regions referred to as "alien islands," frequently surrounded by integrases, transposases, or insertion sequences. This observation implies a potential acquisition of these genes through horizontal gene transfer. This has led to the emergence of drug-resistant *A. baumannii* strains since 1970s (**Kayman Nasr, 2019**).

A. baumannii exhibits inherent resistance to aminopenicillins, first and second-generation cephalosporins, ertapenem, fosfomycin, trimethoprim, aztreonam, and furans (**CA-SFM, 2013**). Furthermore, *A. baumannii* naturally produces a chromosomal oxacillinase known as OXA-51 or OXA-69-like (**Nevgun and al., 2009**). Additionally, non-enzymatic resistance mechanisms involving efflux pumps, membrane permeability, and alterations in the sequence of penicillin-binding proteins (PBPs) have been observed. Moreover, various enzymatic mechanisms, including the production of different β -lactamases, have been reported (**Kumar, S and al., 2020**).

The mechanisms of resistance of *A. baumannii* to β -lactams include both enzymatic resistance and non enzymatic resistance (**Kyriakidis Ioannis and al ., 2021**).

For enzymatic resistance, it involves the production of class A, B, C and D beta-lactamases. The class A beta-lactamases (penicillinases) that confer resistance to penicillin, cephalosporins, monobactam, and carbapenems. Narrow-spectrum lactamase activity, especially against penicillins, inhibited by clavulanic acid extended-spectrum β -lactamase (ESBL) can hydrolyze extended-spectrum cephalosporins such as ceftazidime, ceftriaxone, cefotaxime, and aztreonam. The genes that confer this resistance are: *bla*TEM-92, *bla*SHV, *bla*GES-11, *bla*GES-14, *bla*PER-1, *bla*PER-7, *bla*VEB-and *bla*-CTX-M. (**Poirel, L. and al., 2007**).

Class B beta-lactamases, also known as metallo-beta-lactamases (MBLs), possess the ability to hydrolyze all beta-lactam antibiotics, including carbapenems. MBLs differ from carbapenemases due to the presence of a heavy metal ion, typically zinc, in their active site, which participates in the catalytic activity of these enzymes. They are classified into three subclasses: B1, B2, and B3. Several types of MBLs have been described, including IMP,

Bibliography

NDM, and SIM (**Cornaglia and al., 2011**). Class C beta-lactamases, on the other hand, confer resistance to cephamycins, penicillins, cephalosporins, and beta-lactamase inhibitors but are not inhibited by beta-lactamase inhibitors such as clavulanic acid. *Acinetobacter baumannii*, for example, possesses *AmpC* cephalosporinase (**Jeon and al., 2015**).

Class D beta-lactamases (oxacillinases) constitute a heterogeneous group capable of hydrolyzing oxacillin, cloxacillin, and benzylpenicillin. These enzymes are not inhibited by clavulanic acid or other inhibitors (**Poirel, L and al., 2010**). However, certain enzymes within this class have been shown to be susceptible to inhibition by clavulanic acid, sulbactam, and tazobactam. Some enzymes in this class also exhibit carbapenemase activity and are referred to as carbapenem-hydrolyzing class D beta-lactamases (CHDLs). There are several *blaOXA* genes associated with class D beta-lactamases, including *blaOXA-51*, *blaOXA-23*, *blaOXA-24*, *blaOXA-58*, *blaOXA-143*, and *blaOXA-235* (**Wong and al., 2019**).

Regarding non-enzymatic resistance to beta-lactams, it is caused by mechanisms such as: increases efflux, reduces influx and protects Antibiotic target.

Carbapenem resistance in *A. baumannii* is mediated by multiple mechanisms, including the production of various types of carbapenemases. Ambler class A beta-lactamases, such as *blaKPC-2* and *blaGES-14*, as well as metallo-beta-lactamases, including *blaIMP*-like, *blaVIM*-like, *blaSIM-1*, and *blaNDM-1*, have been implicated in carbapenem resistance (**Bakour and al., 2015**). Additionally, the presence of OXA-type beta-lactamases, such as *blaOXA-23*-like, *blaOXA-24*-like, and *blaOXA-58*-like genes, is associated with increased carbapenem resistance. The expression of these genes is often influenced by the insertion sequence ISAba1 in their promoter region (**M. Nguyen and S.G. Joshi, 2021**). Other mechanisms contributing to carbapenem resistance involve alterations in penicillin-binding proteins (PBPs), leading to reduced drug affinity due to down regulation (**Almasaudi, 2018**). Loss or mutation of outer membrane porins, which are responsible for their

Fluxo antimicrobial agents into the cell, can also contribute to resistance (**Manchanda and al., 2010; D'Souza and al., 2019**). Moreover, the overexpression of efflux pumps, which actively remove antimicrobial agents from the cell, has been observed in carbapenem-resistant strains (**Wong and al., 2019**).

Bibliography

Quinolone resistance is mainly mediated by mutations in the quinolone resistance-determining region (QRDR) of the DNA gyrase gene (*gyrA*) and/or topoisomerase IV gene (*parC*). These changes decrease the affinity of the quinolones binding to the enzyme-DNA complex. (David and *al.* 2015).

Another mechanism of resistance to the quinolone is caused by drug influx and efflux system encoded by chromosomal DNA mediates reduced expression of OMPs involved in drug influx and increased expression of efflux proteins resulting in active drug expulsion; these are also responsible for quinolone resistance. In addition, plasmid-encoded quinolone resistance determinants *qnrA*, *qnrB*, and *qnrS* have also been identified in *Acinetobacter baumannii* that protect DNA by inhibiting binding of quinolones to DNA gyrase and topoisomerase. (Muhammad Asif and *al.*, 2018).

A. baumannii resistance to aminoglycosides primarily results from the inactivation of the antibiotic by certain modifying enzymes, including acetyltransferases, adenylyltransferases, and phosphotransferases. More recently, methylations of the 16S rRNA by methyltransferases, known as 16S rRNA methylases (*ArmA* and *RmtA*), have been described in *A. baumannii* strains isolated worldwide. Additionally, resistance to aminoglycosides is also associated with active efflux mechanisms (Decré, 2012). *A. baumannii* infections are generally defined by resistance to three or more representatives from quinolones, cephalosporins, β -lactams, aminoglycosides and carbapenems family of antibiotics, and the appropriate treatment was colistin, tigecycline, and sulbactam. However, PANDR (Pan Drug-Resistant) phenotypes, which are resistant to all classes of antibiotics, have emerged. The resistance to colistin in CRPA is due to two mechanisms. The first mechanism is phosphoethanolamine addition to the lipid A moiety of lipopolysaccharide (LPS) resulting from mutations in the genes encoding the two component signaling proteins *PmrA* and *PmrB* and second complete loss of LPS production due to mutations in the *lpxA*, *lpxC*, and *lpxD* genes (Muhammad Asif and *al.*, 2018). Many studies have been shown that mutations in the *PmrAB* TCS induce the overexpression of *pmrC*, leading to the modification of lipid A with *PetN* and colistin resistance (Vincent Trebosc and *al.*, 2019).

Bibliography

Recently, a plasmide –mediated colistin resistance gene , specially gene *mcr-1* , has been identified in *Echerichia Coli* , but not in *A.baumannii* .(**Muhammad Asif and al , 2018**). The *mcr* gene reported so far and *mcr -1* is the predominant *mcr* type ,The *mcr -1* which was discovered in more than twenty countries.

The mecanisem of this gene is about phosphoethanolamine transferase enzymes that bind a phosphoethanolamine (PEtN) units on lipid A of outer membrane bacteria Gram negative, which causing arecession of its net negative charge and confers resistance to colistine (**Nadheema Hammood Hussein and al., 2020**). Tigecycline is a glycylycline antibiotic with antimicrobial activity to ribosomal A site of the 30S subunit.

However, tigecycline mecanisme of resistance from the constitutive expression of resistance-nodulation-division (RND) efflux pumps., the most extensively studied RND efflux system in the *adeABC* system. (**Xiaoting Hua and al ., 2021**).

A. Baumannii is considered one of the most critical pathogene for his ability to survive in variaty of environments and his capacity to produce wide range of virulence factors (**Marta Martínez-Gutián and al ., 2019**).

A. baumannii has developed many factors of virulence such as, phospholipases Who are lipolytic enzymes responsible for cleaving phospholipids. These enzymes contribute to the pathogenesis of Gram-negative bacteria by catalyzing the cleavage of phospholipids present in cell membranes and mucosal barriers to facilitate cell lysis and bacterial invasion.

Two phospholipase C (PLC) and three phospholipase D (PLD) enzymes were identified in *A. baumannii*, all with substrate specificity toward the eukaryotic membrane component, phosphatidylcholin (**Michael J and al ., 2012**) , It consists of two PLCs, namely A1S-0043 and A1S-2055. Inactivation of the A1S-0043 gene results in cytotoxicity of epithelial cells (**Sinosh Skariyachan and al . , 2019**)

In addition, the three phospholipase D genes are associated with serum resistance, epithelial cell invasion, and in vivo pathogenic (**McConnell MJ and al., 2013**).

The capsule is considered a virulence factor due to its significant role in protecting bacteria from the host's innate immune response. Numerous studies, including Weber BS, Harding have demonstrated the essentiality of the capsule for the survival of *Acinetobacter*

Bibliography

baumannii during infection and growth in serum (**CM, and Feldman MF 2016**),

Protein secretion systems in Gram-negative bacteria exhibit extensive diversity in terms of function and composition, playing a crucial role as important mediators of virulence. Recent research, as discussed by (**Weber BS, Harding CM, and Feldman MF (2016)**) has elucidated multiple mechanisms by which *Acinetobacter* species secrete proteins and their involvement in the pathogenesis of these bacteria.

In *A.baumannii*, the type two-secretion system, including the genes lipA and lipH, has attracted attention (**Weber BS, Harding CM, Feldman MF, 2016**). This type of secretion system operates through two mechanisms, depending on the Sec/Tat system for substrate translocation to the periplasm (**Eijkelkamp and al., 2014**).

Outer membrane vesicles (OMV) are spherical nano vesicles peric nanovesicles identified in Gram-negative bacteria. They are composed of LPS, outer membrane proteins, periplasmic proteins cytoplasmic, proteins, lipids, DNA and RNA..(**McConnell MJ, Actis L, Pachón J, 2013**). *A. baumannii* secretes OMVs during infections which are also capable of transferring resistance genes, as shown for the blaOXA has been shown for the blaOXA-24-like gene, suggesting a role for these vesicles in spreading in the spread of antibiotic resistance (**Rumbo C and al., 2011**).

Quorum sensing is a ability to sense, respond, and to communicate binding to neighboring cells is critical to the success of the population bacteria detected and respond to hormone. In addition, Quorum sensing contributes to *Acinetobacter* pathogenicity by controlling gene expression , promoting biofilm formation and, consequently, survival and resistance to antibiotics. (**Roca Subirà and al ., 2012**).

Micronutrients are vital for the survival and growth of bacteria. *A.baumannii* has developed various metal systems to scavenge essential nutrients such as zinc, iron, and manganese. In order to acquire these ions. *A.baumannii* produces and secretes siderophores, which are low molecular weight iron scavengers capable of chelating iron with high affinity within the cellular environment (**Sheldon, J.R.; Skaar, E.P, 2020**). Additionally, *A. baumannii* can obtain iron through siderophores. Examples of *A. baumannii* iron chelators include fimsbactins A-F and baumannoferrin A and B, with acinetobactin being the most

Bibliography

characteristic siderophore (**Gaddy JA and al., 2012**).

Outer membrane proteins of Gram-negative bacteria are investigated for their association with antimicrobial resistance, pathogenesis, and variation in the adherence of the host cell.

OmpA of *A. baumannii* is a major surface-bound protein, which facilitates the attachment process and host cell invasion and helps in the commencement of apoptosis at the onset of infection. (**Guo, Y.; Xun, M.; Han, J. A bovine, 2018**).The OmpA adds to the initiation of cell apoptosis, the invasion of epithelial cells, and serum resistance, and others Gram-negative bacteria generally produce outer membrane vesicles.

Another factor of *A. baumannii* is its ability to adhere to both biotic and abiotic surfaces, leading to the formation of biofilms. This process serves as a virulence factor contributing to the pathogenicity of *A. baumannii*. The regulation of biofilm formation involves a wide range of bacterial factors, including pili, outer membrane proteins(OmpA), exopolysaccharide production, and the two-component regulatory system BfmRs. Additionally, cellular and environmental factors such as quorum sensing signaling molecules, temperature, light, and iron availability play a role in this process (**Michael J. McConnell and al., 2013**).

A.baumannii exhibits resistance to certain quaternary ammonium-based disinfectants and can proliferate in disinfectant bottles. Furthermore, it possesses the unique ability to survive for extended periods, exceeding eight days, in a dry environment (**Howard and al., 2012**).

Methodology,
Results and
Discussion

I. Bacterial strains:

A collection of *A. baumannii* strains was compiled between September 2020 and January 2022. These strains were obtained from various samples and isolated by the bacteriology laboratory at the University Hospital of Oran. Subsequently, they were stored and dispatched to the microbiology laboratory at A/MIRA University in Bejaia.

II. Isolation and identification of *A.baumannii*:

A. baumannii, as a distinctive characteristic, has the ability to grow at a temperature of 44°C and does not ferment citrate. To confirm the identification of our strains, we followed the following steps: firstly, we streaked the strains onto Trypticase Soy Agar and incubated them at 44°C for 24 hours. Subsequently, all the colonies that grew were subcultured onto Simons citrate agar and incubated at 37°C for 24 hours.

III. Antibiotics susceptibility studies(antibiograms):

The susceptibility of *A. baumannii* strains to antibiotics is determined by antibiograms. This is carried out on Mueller Hinton agar according to the recommendations of the French Society of Microbiology's (French Antibiogram Committee). (CA-SFM 2018).

Agar plates were inoculated by flooding with a germ suspension. Antibiotic discs were applied to the agar surface using sterile forceps. Plates were incubated for 18 to 24 hours at 37°C. Using a ruler graduated in mm, the different diameters of the zones of inhibition obtained around the antibiotic discs were measured twice, then interpreted as Sensitive (S) Intermediate (I) or Resistant.

Methodology

Table1: The antibiotics tested are listed in TableN°1(CA-SFM 2018).

Antibiotic	Abbreviations	Disc load in(□g)	Critical diameter(mm)	
			S	R
Amikacine	Amk	30	≥19	<19
Ceftazidime	Caz	30	≥18	<15
Ciprofloxacin	CIP	5	≥50	<21
Doxycycline	DOX	30	≥13	<13
Gentamicine	Gen	10	≥17	<17
imipenem	Imp	10	≥24	<21
Levofloxacin	Lvx	5	≥23	<20
Piperacilline	PIP	100	≥21	<18
Triméthoprime sulfametoazole	SXT	1.25-23.75	≥14	<11
Ticarcilline + clavulanic acid	TCC	75-10	≥20	<15
Ticarcilline	TIC	75	≥20	<15
Tobramycine	TOB	10	≥17	<17

S:sensible

R:resistant

Results

Result:

A total of 61 of *A.baumannii* were isolated from different clinical samples.

Phenotype test:

In our study, all 61 strains that were inoculated on tryptic soy agar and incubated at 44 degrees Celsius successfully grew. However, not all strains demonstrated citrate fermentation. These results suggest that they may belong to the *A. baumannii* species. Nevertheless, confirmation of *A. baumannii* presence will require MALDI-TOF identification.




Figure1: citrate test-

Distribution of *A.baumannii* isolates by type of sample:

The figure 2 showed that *A. baumannii* strains are more frequently isolated from PC, blood and pus samples, with rates of 32.75% (20 strains), 27.86% (17 strains) and 26.22% (16 strains) respectively.

Results




Figure2:Distribution of *A.baumannii* strains by type of sample

Distribution of *A.baumannii* strains by department:

During the study period, *A. baumannii* was detected in various departments of Oran Hospital. Figure 3 illustrates the distribution of *A. baumannii* strains by department. The intensive care unit exhibited the highest prevalence of *A. baumannii*, accounting for 44.26% (27 strains), followed by the reaucmc unit with a rate of 14.75% (9 strains). However, a minimal presence of *A. baumannii* was observed in the following departments: PP, Pav-5, IPD, NFC, UMC, , and NCH, with a rate of 1.63%.

Results




Figure3:Distribution of *A. baumannii* strains by department.

Rate of resistance of *A. baumannii* strains to the various antibiotics tested:

The figure 4 showed that ,the highest resistance rate was reported for piperacillin, with a rate of 93.44%, followed by ceftazidime at 91.8%. 86.88% of the strains were resistant to gentamicin, tobramycin, and ticarcillin. Resistance rates of 85.24% were reported for ticarcillin-clavulanic acid and levofloxacin. The resistance rate for imipenem was 83.60%. Lower resistance rates were reported for amikacin, tobramycin, and doxycycline.

Results




Figure4:Rate of resistance of *A.baumannii* strains to the various antibiotics tested.

Distribution of *Acinetobacter baumannii* by sex:

Figure 5 shows the distribution of *Acinetobacter baumannii* by sex: 54.09% in the female category with 33 strains, compared with 45.90% in the male category with 28 strains.




Figure5:Distribution of *Acinetobacter baumannii* by sex.

Discussion

A. baumannii has been widely acknowledged as an opportunistic microorganism and has now emerged as a significant cause of hospital-acquired infections (**Giamarellou et al., 2008**). According to the Algerian surveillance network, *A. baumannii* accounts for 61.67% of infections in Algeria (**Rahal, 2020**). Our study detected the presence of *A. baumannii* in various departments, including infectious and parasitic diseases, internal medicine A, gastroenterology, dermatology, pneumo-phtisiology, surgical clinic A, and NouarFadela clinic (obesity clinic and gynecology).

Multiple studies have consistently reported the high prevalence of *A. baumannii* infections in intensivecare units(ICUs) (**Elouennassetal.,2003;Al-Agamy etal.,2014**). Our findings support the existing literature, indicating that ICUs remain the primary source of *A. baumannii* infections, although the rates may vary. In our study, *A. baumannii* strains were predominantly isolated from the ICU (44.26%). These results align with numerous studies, notably Lahsoune et al.'s (2007) study conducted in Morocco, which reported arate of 50.30%, and the study by Mina and Namigandain 2018 at Beni Messous Hospital in Blida,Algeria, which also reported a rate of 50%.(**Namiganda and Mina.,2018**)

The persistence of *A. baumannii* infections in ICUs can be attributed to various factors. Major predisposing factors for acquiring *A. baumannii* infection include prolonged hospital stays, mechanical ventilation, intravascular devices, advanced age, immunosuppression, previous broad-spectrum antimicrobial therapy, previous sepsis, ICU stays, and enteral feedings (**Dr. Shalini Singh andal., 2022**).

Regarding the types of samples from which *A. baumannii* strains were isolated in our study, the respiratory site was the primary site of infection, accounting for 32.75% of isolates from protected distal sampling. This was followed by 27.86% of isolates from bloodsamplesand4.91%from catheterization. Our find ingsalign with a study conducted

Discussion

by R. Rada and *al* in 2022, which reported similar rates , 38% from the respiratory site and 4% from catheterization.(**R. Rada and *al.*, 2022**) However, our results contradict those obtained in another study conducted by (**Abir Ramoul and *al.*,2016**).

In our study, *A. baumannii* strains were predominantly isolated from female patients, accounting for a high rate of 54.09%. In comparison, the male category had a slightly lowerrateof45.90%.These findings align with there results reported by Shristi Raut and *al.* 2020, who observed rates of 43.50% and 56.50% for females and males, respectively (**ShristiRaut and *al.* 2020**).

It is important to note that these results may vary depending on the types of infection and hospital wards.The literature includes several etiological studies that suggest no significant difference between sexes in the acquisition of *Acinetobacter* spp. Infection(**Shristi Raut and *al.* 2020**).

The resistance rates of *A. baumannii* to different classes of antibiotics vary. In our study, we observed high rates of resistance to β -lactam antibiotics, with 93.44% resistance to piperacillin, 91.80% to ceftazidim, and 86.88% to ticarcillin. These findings closely align with the results obtained by Zaidi in 2014 who reported a resistance rate of 89.58% for the same compounds.(**Zaidi .FT ,2014**) Another study conducted by Benamrouche and *al.* in 2020 from various hospitals in Algeria also found similar resistance rates(**Benamrouche and *al.*, 2020**)

Regarding aminoglycosides, we observed resistance rates of 86.88% for gentamicin, 52.45% for tobramycin, and 70.40% for amikacin in our study. These results are higher than those reported by Bakourand*al*2012. Resistance to aminoglycosides can be attributed to multiple mechanisms with the production of modifying enzymes and

Discussion

Methylation of rRNA16S by armA being them most common resistance mechanisms

(Lambertetal.,2006)

The resistance of *A.baumannii* to carbapenems has significantly increased in recent decades, largely due to the overuse of this class of antibiotics in hospital settings **(Chabaniandal., 2004; Ling andal., 2005; Picazoandal., 2006)**. Our study revealed a high level of resistance to imipenem, with a rate of 83.60%. This rate is higher than the 82% reported by Bentara and Abdelli 2015 **(Bentara and Abdelli 2015)**. The elevated resistance to imipenem is concerning as it poses challenges to patients'treatment regimens, especially in intensive care units where imipenem is the preferred antibiotic for the treatment of nosocomial infections .**((Bakourand al., 2012)**.

The emergence of carbapenem resistance is mainly attributed to the production of carbapenemases, including class D carbapenem-hydrolyzing oxacillinases and, less frequently, class B metallo- β -lactamases. Class D oxacillinases in *A. baumannii* are predominantly represented by the blaOXA-23, blaOXA-24, and blaOXA-58 genes **(Peleg, 2008; Kempf, 2012)**.

In our study, 86.88% of isolates showed resistance to fluoroquinolones. Ben Haj Khedher, 2010? reported a resistance rate of 92.3% to ciprofloxacin in Tunisian hospitals **(Ben Haj Khedher, 2010)**. According to the national network for monitoring resistant bacteria in Algeria in 2020, the resistance rate to ciprofloxacin was 89.58% in 20 laboratorie**(Rahal, 2020)**

Colistin is a highly effective antibiotic against strains of *A.baumannii*. However,the increasing use of colistin as monotherapy for the treatment of bacterial infections caused by multidrug-resistant *A.baumannii* strains

Discussion

Heterogeneous resistance to this class of antibiotics (**BenHajKhalifaandKhedher,2010; Al-Sweith and *al.*, 2012**).

In Algeria, colistin resistance in *A. baumannii* was first detected in 2014 by Bakour and *al.* This resistance is associated with a mutation in the *pmrB* gene (**Bakour and *al.*, 2014**).

To maintain the effectiveness of colistin, studies suggest the combination of colistin with other antibiotics such as rifampicin (**Frasca and *al.*, 2008**). Furthermore, there is a need to develop and evaluate new strategies , such as the combination of colistin with tigecycline (**Giamarellou and *al.*, 2008**).

Conclusion

This research work focused on the mechanism of multi-resistant *A.baumannii* in the EHU of Oran.

Our results show that *Acinetobacter baumannii* occupies an important place among opportunistic germs due to its ability to cause nosocomial infections, and that it is presented more specifically in intensive care units.

Currently in Algeria, resistances to the many antibiotics in terms of morbidity, mortality due to the several factors essentially increase the duration of hospitalization.

In this is why epidemiological investigations in intensive care units are essential to control the emergence of this species.

The study we carried out enabled us to obtain the following results:

- 61 strains of *acinetobacter baumannii* were isolated at the Etablissement hospitalier d'Oran.
- The majority of strains come from pulmonary samples and essentially from the reanimation department with a rate of 44.26 %.
- A huge increase in resistance to beta-lactam carbapenem antibiotics.

The results obtained in this study must be completed by a series of other tests, namely:

- Identification and characterisation of the genetic environment. (Insertion sequences, integrons and transposons,.) In order to determine the elements that mobility of genes resistance .
- Study of the genetic carriers (plasmid or chromosomal) responsible for possible dissemination of antibiotic resistance in *A.baumannii*.

In order to combat the emergence of these multi-resistant strains in our hospitals, we recommend: setting up a system for monitoring the hospital environment and strictly hygiene measures , Equipping laboratories with tools for the rapid identification and detection of resistance to these bacteria , Making hospital visits or aware of the risks of direct contact with patients and the hospital environment.

Referances

A

Anton Y.Peleg, Harald Seifert, and David L.Paterson.(2008).Acinetobacter baumannii: Emergence of a Successful Pathogen. CLINICAL MICROBIOLOGY REVIEWS.21(3). doi:10.1128/CMR.00058-07.

AoifeHowarda , Michael O'Donoghuea , Audrey Feeneya& Roy D. Sleator.(2012). Acinetobacter baumannii An emerging opportunistic pathogen. Virulence,3: 3,243-250,DOI: 10.4161/viru.19700.

Allal Hassiba and HadbiManel.(2018).sur les infection *Acenitobacter baumannii* à l'hôpital Belloua de Tizi Ouzou. Mémoire fin de cycle .

Abir Ramoul, Lotfi Loucifa,d , Sofiane Bakour, Sabrina Amiri, Mazouz Dekhil, Jean-MarcRolain.(2016).Co-occurrence of blaNDM-1 with blaOXA-23or blaOXA-58in clinical multidrug-resistant Acinetobacter baumannii isolates in Algeria. . Journal of Global Antimicrobial Resistance.

B

Brisou J, Prevot A,editors.(1954)..Studies on bacterial taxonomy .X. The revision of species under Acromobacter group. Annales de l'Institut Pasteur.

Bakour S, Kempf M ,Touati A ,AitAmeur A ,Haouchine D , Sahli F ,Rolain JM.(2012). Carbapenemase-producing Acinetobacter baumannii in two university hospitals in Algeria. J Med Microbiol. 61: 1341-1343.

Ben Haj Khalifa A. et Khedher M. (2010). Profil de sensibilité aux antibiotiques des souchesd' A.baumannii isolées dans la région de Mahdia.MédMalad Infect.40:126-128.

Bakour S, Touati A, Bachiri T, Sahli F, Tiouit D, Naim M, Azouaou M, Rolain JM. (2014).First report of 16SrRN Amethylase ArmA-producing Acinetobacter baumannii and spread of metallo- β -lactamaseNDM-1in Algerian hospitals.JInfectChemother.20:696- 701.

Bentara Hanane et Abdelli Fouzia.(2015).Caractérisation phénotypique de la résistance aux β -lactamines des souches d'Acinetobacter baumannii isolées à l'Etablissement Hospitalier Universitaire d'Oran.(mémoire fin de cycle).

Referances

Abila Benamrouche ,Ourida Lafer, Lahcen Benmahdi, Akila Benslimani, Wahiba Amhis ,Houria Ammari5, Farida Assaous, Amina Azzam, Kheira Rahal, Hassiba Tali Maamar(2020

C

Comité de l'antibiogramme de la société française de microbiologie :recommandations 2013.

Chabani F,ZoughaghiL, Taouragt K ,Arab H, et Benaouda A.(2004).Acinetobacter baumannii : épidémiologie et résistance aux antibiotiques. Prat. 14(2): 23-4.

Comité de l'antibiogramme de la société française de microbiologie: recommandations 2018

D

Decré D.(2012).Acinetobacter baumannii et résistance aux antibiotiques :Un modèle d'adaptation. Revue Francophone des laboratoires. 441: 43–52.

David c. hopper and George A.jacobay.(2015).Mechanisms of drug resistance :quinolone resistance. Antimicrobial Therapeutics Reviews, doi : 10.1111/nyas.12830

E

Eijkelkamp A Bart Uwe H Stroehler , Karl A Hassan, Ian T Paulsen and Melissa H Brown.(2014). Comparative analysis of surface-exposed virulence factors of Acinetobacter baumannii. BMC Genomics ,Doi : 10.1186/1471-2164-15-1020

Elouennass M., Bajou T., Lemnouer A. H., Foissaud V., Hervé V. et Baaj A.J. (2003). Acinetobacter baumannii: susceptibility of strains identified in the military in struction hospital Mohammed V, Rabat, Morocco. MédMalad infect. 33: 361-364

F

FaribaAkramia and Amirmorteza Ebrahimzadeh Namvar.(2019). Acinetobacter baumannii as Nosocomial Pathogenic Bacteria, Molecular Genetics, Microbiology and Virology , 34(2) , DOI: 10.3103/S0891416819020046.

Referances

Frasca D, Dahyot-Fizelier C, Mimoz O. (2008). La colistine en réanimation. *Journal home.* 7: 251-258.

G

Giuseppe Cornaglia, Helen Giamarellou, Gian Maria Rossolini.(2011). Metallo- β -lactamases: a last frontier for β -lactams. Review, doi.org/10.1016/S1473-3099(11)70056-1.

Gaddy JA, Arivett BA, McConnell MJ, Lopez-Rojas R, Pachon J, ActisLA .(2012). Role of acinetobactin-mediated iron acquisition functions in the interaction of *Acinetobacter baumannii* strain ATCC 19606T with human lung epithelial cells, *Galleria mellonella* caterpillars, and mice. *Infect Immun.*;80(3):1015-24.

Gati Noble Selasi, Asiimwe Nicholas, Hyejin Jeon, Yoo Chul Lee, Jeong Rae Yoo , Sang Taek Heo , Je Chul Lee.(2015). Genetic basis of antimicrobial resistance and clonal dynamics of carbapenem-resistant *Acinetobacter baumannii* sequence type 191 in a Korean hospital. *Infection, Genetics and Evolution.*

Giamarellou H, Antoniadou A et Kanellakopoulou K. (2008). *Acinetobacter baumannii*: a universal threat to public health?. *International Journal of Antimicrobial Agents.*

H

Hua Zhou, PhDa , Yake Yao, PhDa , Bingquan Zhu, MD b , Danhong Ren, MD c , Qing Yang, MD d , Yiqi Fu, PhDa , Yunsong Yu, PhDe , Jianying Zhou, MD a .(2019). Risk factors for acquisition and mortality of multidrug-resistant *Acinetobacter baumannii* bacteremia: A retrospective study from a Chinese hospital *Medicine*, Doi : 10.1097/MD.00000000000014937.

Hamel James Doughari, Patrick Alois Ndakidemi , Izzane Susan Human and Spinnney Benade .(2011). The Ecology, Biology and Pathogenesis of *Acinetobacter* spp.: An Overview. *Microbes Environ.* Vol, Doi : 26, 10.1264/jsme2.ME10179

Hing Jian Mea a , Phelim Voon Chen Yong a , Eng Hwa Wong.(2021). An overview of *Acinetobacter baumannii* pathogenesis: Motility, adherence and biofilm formation. *Microbiological Research*

Referances

J

Jaejoon Jung & Woojun Park.(2015). Acinetobacter species as model microorganisms in environmental microbiology: current state and perspectives. Appl Microbiol Biotechnol, DOI10.1007/s00253-015-6439-y.

K

Kyriacos C Nicolaou and Stephan Rigol.(2018). A brief history of antibiotics and select advances in their synthesis. The Journal of Antibiotics., doi.org/10.1038/ja.2017.62.

Kyriakidis, I.; Vasileiou, E.; Pana, Z.D.(2021). Tragiannidis, A. Acinetobacter baumannii Antibiotic Resistance Mechanisms. Pathogens ,10, 373, doi.org/10.3390/pathogens10030373

L

Lenie Dijkshoorn, Alexandr Nemeč and Harald Seifert.(2008). An increasing threat in hospitals : multidrug –resistant acinetobacter baumannii. Revidés ,doi .org/10.1038/nmicro1789.

Lambert T.(2006). Aminocyclitol et bactéries à Gram négatif. In: Courvalin P, Leclerc R, Bingen E. 2^{ème} AntibioGramme. Paris: ESKA. 227-244

M

Michael J, McConnell Luis Actis & Jeronimopacho'n.(2013). human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Reviews .37. DOI: 10.1111/j.1574-6976.2012.00344.x..

Muhammad Asif, Iqbal Ahmad Alvi, Shafiq Ur Rehman.(2018). Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infection and Drug Resistance. 11. Doi :10.2147/IDR.S166750.

M. Nguyen and S.G. Joshi.(2021). Carbapenem resistance in Acinetobacter baumannii, and their importance in hospital-acquired infections: a scientific review. Journal of Applied Microbiology , doi:10.1111/jam.15130.

Referances

McConnell MJ, Actis L, Pachón J. (2013). *Acinetobacter baumannii*: human infections, factors contributing to pathogenesis and animal models. *FEMS Microbiol Rev.* 37: 130-155, DOI: 10.1111/j.1574-6976.2012.00344.x

Matt Hutchings¹ , Andrew Truman² and Barrie Wilkinson.(2019). Antibiotics: past, present and future. *Current Opinion in Microbiology*, 51:72–80
,Doi :10.1016/j.mib.2019.10.008

Marta Martínez-Gutián, Juan C. Vázquez-Ucha, a Laura Álvarez-Fraga ,a Kelly Conde-Pérez, Juan A. Vallejo, Alejandra Perina, Germán Bou, Margarita Poza, and Alejandro Beceiro . Global Transcriptomic Analysis During Murine Pneumonia Infection Reveals New Virulence Factors in *Acinetobacter baumannii*. *The Journal of Infectious Diseases*, Doi .org/10.1093/infdis/jiaa522.

N

Nabil A Nimer .(2022) .Nosocomial Infection and Antibiotic-Resistant Threat in the Middle East. *Infection and Drug Resistance*, , 631-639, DOI: 10.2147/IDR.S351755

Nevgun Ozen ,Ayla Ergani, Thierry Naas, Dilara Öünç¹ , Meral Gültekin , Dilek Colak and Patrice Nordmann.(2009). Outbreak of Carbapenem-Resistant *Acinetobacter baumannii* Producing the Carbapenemase OXA-58 in Turkey, *The Open Antimicrobial Agents Journal*, DOI: 10.2174/1876518100901010001.

Nadheemhammood Hussein. israa M.S. AL-Kadmy. Buntheina MohammedTaha

.Jumaah Dakel Hussein .(2021). Mobilized colistine resistance (*mcr*) gene from 1 to 10 : a comprehensive review. *Molecular Biology Reports* , DOI .org/10.1007/s11033-021-06307-y

Namiganda Victoria and Mina Yousra .(2018). Réalisé aux laboratoires de microbiologie du CHU de Bénimes sous et de Biologie des systèmes microbians (LBSM), ENS de Kouba.

Mémoire de cycle.

Nabila Benamrouche, Ourida Lafer, Lahcen Benmahdi, Akila Benslimani, Wahiba Amhis, Houria Ammari⁵, Farida Assaous, Amina Azzam⁶, Kheira Rahal, Hassiba Tali Maamar.(2009). Phenotypic and genotypic characterization of multidrug-resistant *Acinetobacter baumannii* isolated in Algerian hospitals.

Referances

P

Pawel Nowak, Paulina Paluchowska.(2016). Acinetobacter baumannii: biology and drug resistance-role of carbapenemases. Folia History chemiaet cytobiologica, DOI: 10.56.03/FHC.a2016.009.

PaymanNasr. (2019). Genetics, Epidemiology and Clinical Manifestations of Multidrug- Resistant Acinetobacter baumannii. Journal of Hospital Infection, <https://doi.org/10.1016/j.jhin.2019.09.021>.

Poirel L, Nordmann P. (2008). Acinetobacter baumannii: Mechanisms of Resistance, Multipleβ-lactamases. Acinetobacter Biology and Pathogenesis. Ds. SpringerSc.129-143

R

RahalKM.(2020).Réseau Algérien de surveillance de la résistance des bactéries aux antibiotiques. [http://www.sante.dz/aarn/documents/pdf/rapport 13.pdf](http://www.sante.dz/aarn/documents/pdf/rapport%2013.pdf).

Rumbo C, Fernández-Moreira E, Merino M, Poza M, Mendez JA, Soares NC, et al. (2011). Horizontal transfer of the OXA-24 carbapenemase gene via outer membrane vesicles: a new mechanism of dissemination of the carbapenem resistance genes in Acinetobacter baumannii. Antimicrobial agents and chemotherapy.

Roca Subirà I, Espinal P, Vila-Farrés X, Vila EstapéJ.(2012). The Acinetobacter baumannii oxymoron: commensal hospital dweller turned pan-drug-resistant menace. Frontiers in microbiology.

R. Rada1, R. Nakhli , S. Khayati , L. Ait Said , K. Zahlane.(2022). Epidemiological Aspect and Antibiotic Resistance Profile of Acinetobacter baumannii in the Resuscitation Department of Ibn To fail Hospital CHU Med V. Haya: The Saudi Journal of Life Sciences.

S

Santosh Kumar Yadav, Rajshree Bhujel, Pradip Ha mal, Shyam Kumar Mishra, Sangita Sharma &JeevanBahadurSherchand.(2020). Burden of Multidrug-Resistant Acinetobacter baumannii Infection in Hospitalized Patients in a Tertiary Care Hospital of Nepal. Infection and Drug Resistance. 725-732, DOI: 10.2147/IDR.S239514.

Referances

Saad B. Almasaudi. (2018). Acinetobacter spp. as nosocomial pathogens: epidemiology and resistance features. Saudi Journal of Biological sciences ,<http://dx.doi.org/10.1016/j.sjbs.2016.02.009>

Sofiane Bakour, Abiola Olumuyiwa Olaitan, Houria Ammari,3 Abdelaziz Touati,2Souad Saoudi,2 Kenza Saoudi,2 and Jean-Marc Rolain.(2015). Emergence of Colistin-and Carbapenem-Resistant Acinetobacter baumannii ST2 Clinical Isolate in Algeria: First Case Report. EPIDEMIOLOGY, DOI: 10.1089/mdr.2014.0214 .

Soumia Brahmi, Abdelaziz Touati,b Axelle Cadière, Nassima Djahmi, Alix Pantel, Albert Sotto,a Jean-Philippe Lavigne ,Catherine Dunyach-Remy .(2012) . First description of two OXA-23-mediated carbapenem resistance in Sequence Type Acinetobacter baumannii isolates in Pagellus acarne fished in the Mediterranean Sea afar Bejaia (Algeria) . Short-FormPaper .

Shristi Raut1 Komal Raj Rijal SulochanaKhatiwada Subash Karna1 Rita Khanal1 JanakAdhikariBipinAdhikari.(2018). Trend and Characteristics of Acinetobacter baumannii Infections in Patients Attending Universal College of Medical Sciences, Bhairahawa, Western Nepal: A Longitudinal Study of 2018

Sheldon JR, SkaarEP .(2020) Acinetobacter baumannii can use multiple siderophores for iron acquisition, but only acinetobacter inisrequired for virulence. PLoSPathog ,16(10), doi.org/10.1371/journal.ppat.1008995.

v

VikasManchanda, SinhaSanchaita1,SinghNP.(2010).Multidrug Resistant Acinetobacter., Symposium on infectious agents in a multidrug resistant globe ,Doi :10.4103/0974-777X.68538.

VishvanathTiwari. (2018). Post-translational modification of ESKAPE pathogens as a potential target in drug discovery. Drug Discovery Today.

w

WayanSuranadi,NiNengahDwiFatmawati,IWayanAryabiantara,Cynthia DewiSinardja,DarmawanJayaSaputra.(2019).Acinetobacter baumanniii an

Referances

Opportunistic pathogenasanM DROinICU. BaliJournal of Anesthesiology(BJOA),3(2), 150-153, 10.15562/bjoa.v3i2.199.

Wong, M.H.-Y.; Chan, B.K.-W.; Chan, E.W.-C.; Chen, S.(2019). Over-Expression of ISAbal-Linked Intrinsic and ExogenouslyAcquired OXA Type Carbapenem-Hydrolyzing-ClassD-β-Lactamase-EncodingGenesIsKeyMechanismUnderlyingCarbapenemResistance in Acinetobacter baumannii. Front microbiol ,doi .org/10.3389/fmicb.2019.02809.

WandaCReygaer.(2018).An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiology. <http://www.aimspress.com/journal/microbiology>

WeberBS,HardingCM,FeldmanMF.(2016).PathogenicAcinetobacter:fromthecell surface to infinity and beyond. Journal of bacteriology. .198(6):880-7

x

Xiaoting Hua, Jintao He, Jingfen Wang, Linghong Zhang, Linyue Zhang, Qingye Xu, Keren Shi, SebastianLeptihn, Yue Shi, Xiaoting Fu, Pengfei Zhu, Paul G. Higgins &YunsongYu (2021) Noveltige cycline resistance mechanisms in Acinetobacter baumannii mediated by mutations in adeS,rpoBandrrf ,Emerging Microbes &Infections,10:1,1404- 1417, DOI: 10.1080/22221751.2021.194880

z

Zaidi FZ. (2014). Caracterisation des mécanismes de resistances aux β-lactamines chez des souches d'Acinetobacter baumannii isolées à l'Établissement hospitalier universitaire d'Oran. Mémoire de Master. Option : Microbiologie Moléculaire et Médical. Université d'Abderrahman MIRA. Faculté des Sciences de la Nature et de la Vie. 579MAS /130

Annexes

Composition of culture media(g/l).

Simmons citrate medium composition.

Citrate de sodium	1.0g
Bleu de bromothymol	0.08g
Chlorure de sodium	5.0g
Sulfate de magnésium	0.2g
Hydrogénophosphate de potassium	1.0g

Gélose trypticase soja composition

Digestion pancréatique de caséine	1
Peptone de Soja	5g
Chlorure de sodium	5g
Gélose	5g
PH 7.3±0.2 à 25 C	

Gélose trypticase soy broth composition

Tryptophane	17.0
Chlorure de sodium	5.0 g

Annexes

Phosphatedipotassique	2.5
Peptonedesoja	3.0 g
Glucose	2.5 g
PH7.3±0.2 à 25 C	

Annexes

Equipment:

- Bunsenburner.
- Pasteur pipettes
- Petridishes.
- Platinum loop
- Oven
- Forceps.
- Antibioticdiscs.

TableN°II:Characteristics of the *A. baumannii* strains collected.

Code	Date	sex	Department	sampling
709	23/09/2020	F	ream	Protecteddistal
721	27/09/2020	M	reap	Pus
592	29/09/2020	F	ream	blood
737	01/10/2020	M	reaumc	Protecteddistal
699	17/11/2020	M	ream	Blood
720	25/11/2020	M	marfan	catheter
218	24/02/2021	M	ream	Protecteddistal
287	21/03/2021	M	reaumc	Pus
468	26/04/2021	F	ream	Pus
483	29/04/21	F	ima	pus
736	23/06/21	M	nch	csf
740	27/06/21	M	sca	pus
1016	31/08/21	F	marfan	Ascritesfluid
600	14/09/21	M	marfan	blood
1128	11/02/20	F	reap	csf
907	27/11/2022	F	resu	Protecteddistal
770	16/12/22	F	resu	bood
978	20/12/20	F	resu	Protecteddistal
155	02/07/21	F	resu	Protecteddistal
211	23/02/21	M	resu	Protecteddistal
255	03/07/21	M	resu	Protecteddistal

Annexes

109	04/01/21	M	reaumc	Protecteddistal
361	04/02/21	M	reaumc	Protecteddistal

Annexes

419	13/4/2021	F	resu	pus
471	05/02/21	M	pp	Fluidliquid
601	31/05/21	M	reaumc	Protecteddistal
801	13/07/21	M	reaumc	pus
813	16/07/21	M	resu	Protecteddistal
506	18/07/21	F	mat	blood
823	22/07/21	F	reap	pus
525	27/07/21	M	marfan	Blood
850	29/07/21	F	reaumc	Protecteddistal
549	8/08/21	F	resu	blood
549	11/08/21	F	resu	Protecteddistal
549	18/08/21	F	resu	Protecteddistal
549	29/08/21	M	reap	tr
549	29/08/21	F	reaumc	blood
549	30/08/21	F	resu	Protecteddistal
549	30/08/21	F	resu	Protecteddistal
549	21/09/21	F	resu	blood
549	23/09/21	M	reap	pus
549	23/09/21	M	reap	pus
549	31/10/21	M	resu	blood
549	15/11/2021	M	pav.5	blood
549	17/11/21	F	resu	Protecteddistal
549	23/11/21	F	pav.7	Blood
549	28/11/21	F	pav.7	Pus
549	12/06/2021	F	resu	Protecteddistal
549	12/11/2021	F	resu	Protecteddistal
549	12/12/2021	M	ipd	Pus
549	13/12/2021	F	reap	Pus
549	15/12/2021	F	resu	Blood
549	20/12/2021	M	resu	Catheter
549	28/12/2021	F	ima	Pus
549	29/12/2021	M	nfc	Catheter
549	01/02/2022	F	reap	Blood
549	01/04/2022	F	Mat	Blood

Annexes

549	01/11/2022	M	resu	Protecteddistal
549	23/01/2022	M	reaumc	Blood
549	26/01/2022	F	resu	Protecteddistal

M:male **F:**femaleresu;resuscitation

Résumé:

Les bactéries à gram négatif non fermentaire sont des pathogènes opportunistes due a leur capacité de provoquer des infections nosocomiales.; elles ce manifeste a une résistance aux antibiotique, dont l'espèce *Acinetobacter Baumann*, qui pose un réel problème sur la santé humaine .

Objectif de ce travail est la caractérisation phénotypique et génotypique des mécanismes de résistances d'*Acinetobacter baumannii* aux différents antibiotiques, isolées dans différents services entre septembre 2020 et janvier 2022 au niveau l'EHU d'Oran.

L'étude de la résistance in vitro de ces germes vis-à-vis aux β -lactamines, aminosides, fluroquinolones, Aminoglycosides par la méthode des disques selon la société française de microbiologie (CA-SFM).

La résistance aux β -lactamines est due, soit à la production d'une BLSE, ou à la production des carbapénémases, dans point génétiques par la production des gènes de résistance tels que OXA-23 et NDM-1.

A fin de combattre cette émergence d'*Acinetobacter baumannii* multi résistantes qui pose un sérieux problèmes dans secteur thérapeutiques, d'où la nécessité de l'applications des règles d'hygiènes .

Mot clé: *Acinetobacter baumannii* Etablissement hospitalier universitaire d'Oran β – lactamines

Abstract

Non-fermentative gram-negative bacteria are opportunistic pathogens due to their ability to cause nosocomial infections; they manifest resistance to antibiotics, including the species *Acinetobacter baumannii*, which poses a real problem for human health.

The objectif of this work is to characterise the phenotypic and genotypic resistance mechanisms of *Acinetobacter baumannii* to different antibiotics, isolated in different departments between September 2020 and January 2022 at the EHU of Oran.

The study of in vitro resistance of these germsto β -lactams, aminoglycosides, fluroquinolones and aminoglycosides using the disc method according to the French Microbiology Society (CA-SFM).

Resistance to β -lactamsis due either to the production of an ESBL, or to the production of carbapenemases, in genetic points by the production of resistance genes such as OXA-23 and NDM-1.

In order to combat this emergence of multi-resistant *Acinetobacter baumannii*, which posseserious problems in the therapeutic sector, it is essential to apply hygiene rules.

Keywords: Establishing Hospital University of Oran, *Acinetobacter baumannii*, antibiotic, β -lactams, resistance phenotypes